JP2012504589A5 - - Google Patents

Download PDF

Info

Publication number
JP2012504589A5
JP2012504589A5 JP2011529634A JP2011529634A JP2012504589A5 JP 2012504589 A5 JP2012504589 A5 JP 2012504589A5 JP 2011529634 A JP2011529634 A JP 2011529634A JP 2011529634 A JP2011529634 A JP 2011529634A JP 2012504589 A5 JP2012504589 A5 JP 2012504589A5
Authority
JP
Japan
Prior art keywords
anthrax
range
vaccine according
anthrax vaccine
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011529634A
Other languages
English (en)
Japanese (ja)
Other versions
JP5701760B2 (ja
JP2012504589A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2009/051293 external-priority patent/WO2010038076A1/en
Publication of JP2012504589A publication Critical patent/JP2012504589A/ja
Publication of JP2012504589A5 publication Critical patent/JP2012504589A5/ja
Application granted granted Critical
Publication of JP5701760B2 publication Critical patent/JP5701760B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011529634A 2008-10-02 2009-10-02 炭疽菌ワクチン製剤とその用途 Expired - Fee Related JP5701760B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19496708P 2008-10-02 2008-10-02
US61/194,967 2008-10-02
PCT/GB2009/051293 WO2010038076A1 (en) 2008-10-02 2009-10-02 Anthrax vaccine formulation and uses thereof

Publications (3)

Publication Number Publication Date
JP2012504589A JP2012504589A (ja) 2012-02-23
JP2012504589A5 true JP2012504589A5 (enExample) 2012-11-22
JP5701760B2 JP5701760B2 (ja) 2015-04-15

Family

ID=41292568

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011529634A Expired - Fee Related JP5701760B2 (ja) 2008-10-02 2009-10-02 炭疽菌ワクチン製剤とその用途

Country Status (7)

Country Link
US (1) US9616117B2 (enExample)
EP (1) EP2344188B1 (enExample)
JP (1) JP5701760B2 (enExample)
AU (1) AU2009299615B2 (enExample)
CA (1) CA2738621C (enExample)
IL (1) IL212118A (enExample)
WO (1) WO2010038076A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009299615B2 (en) 2008-10-02 2015-07-16 Pharmathene Inc. Anthrax vaccine formulation and uses thereof
WO2014134187A1 (en) * 2013-02-26 2014-09-04 The Regents Of The University Of California Compositions and methods for the treatment of cancer

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK140815B (da) * 1975-06-10 1979-11-19 Weeke Bengt Fremgangsmåde til påvisning eller bestemmelse af antistoffer i legemsvæsker ved hjælp af kendte antigener eller til bestemmelse af antigener ved hjælp af kendte antistoffer fra legemsvæsker samt et middel til anvendelse ved udøvelse af fremgangsmåden.
DE2632478A1 (de) 1975-07-23 1977-02-24 Coulter Electronics Verfahren zur erfassung und trennung von antigenen und antikoerperchen im blut und in anderen proben
US4486530A (en) * 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
ATE68524T1 (de) * 1985-07-09 1991-11-15 Quadrant Bioresources Ltd Beschuetzung von proteinen und aehnlichem.
US5690942A (en) 1995-06-02 1997-11-25 American Home Products Corporation Adjuvants for viral vaccines
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9618107D0 (en) 1996-08-30 1996-10-09 Secr Defence Vaccine production
US20020120228A1 (en) * 2000-06-08 2002-08-29 Yuh-Fun Maa Powder compositions
KR20030020294A (ko) 2000-06-08 2003-03-08 파우더젝트 백신, 인코포레이티드 분말 조성물
GB0016702D0 (en) 2000-07-08 2000-08-23 Secr Defence Brit Expression system
WO2002100340A2 (en) 2001-06-08 2002-12-19 Avant Immunotherapeutics, Inc. Improved vaccination against anthrax
GB0118249D0 (en) * 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0126266D0 (en) * 2001-11-01 2002-01-02 Microbiological Res Authority Anthrax antigenic compositions
UA80809C2 (en) 2001-11-05 2007-11-12 Process for preparation of protective antigen protein of anthracis with e.coli
US7888490B2 (en) 2001-12-05 2011-02-15 Centre of Biotechnology Jawaharlal Nehru University Process for the preparation of non-toxic anthrax vaccine
ATE503491T1 (de) 2003-02-13 2011-04-15 Becton Dickinson Co Verbesserte anthraximpfstoffe und abgabeverfahren
EP1755677A4 (en) 2004-06-14 2009-11-25 Medimmune Vaccines Inc HIGH-PRESSURE SPRAY DRYING OF BIOACTIVE MATERIALS
US7355027B2 (en) 2004-06-16 2008-04-08 Dynport Vaccine Company Llc Bacillus anthracis protective antigen
JP2008514644A (ja) 2004-09-28 2008-05-08 アルザ コーポレイション ミョウバンアジュバント免疫活性剤の安定化
GB0525213D0 (en) 2005-12-12 2006-01-18 Secr Defence Vaccine
WO2008048344A2 (en) * 2006-02-13 2008-04-24 Fraunhofer Usa, Inc. Bacillus anthracis antigens, vaccine compositions, and related methods
GB0607462D0 (en) 2006-04-13 2006-05-24 Avecia Ltd Assay
JP2010502747A (ja) 2006-09-08 2010-01-28 ベクトン・ディキンソン・アンド・カンパニー ミョウバン吸着ワクチンの安定粉末製剤
EP1972347A1 (en) 2007-03-19 2008-09-24 Becton, Dickinson and Company, Wagner, Jaconda Stable vaccine powder formulations
WO2008152654A1 (en) 2007-06-11 2008-12-18 Panacea Biotec Limited Anthrax fusion proteins, compositions and uses thereof
GB0801122D0 (en) * 2008-01-22 2008-02-27 Avecia Biolog Ltd Vaccine composition
AU2009299615B2 (en) 2008-10-02 2015-07-16 Pharmathene Inc. Anthrax vaccine formulation and uses thereof
WO2010084298A1 (en) 2009-01-22 2010-07-29 Pharmathene Uk Limited Stable vaccine compositions and methods of use

Similar Documents

Publication Publication Date Title
WO2007095976A3 (de) Adjuvanz in form einer lipid-modifizierten nukleinsäure
JP2014051497A5 (enExample)
JP2016513638A5 (enExample)
JP2013509429A5 (enExample)
JP2010529999A5 (enExample)
JP2016040284A5 (enExample)
JP2013520405A5 (enExample)
JP2011250797A5 (enExample)
JP2011522816A5 (enExample)
EP1708749A4 (en) BACTERIAL FLAGELLINS CONTAINING VACCINE ADJUVANTIES FOR MUCOSAL USE AS ACTIVE COMPONENTS
JP2013534248A5 (enExample)
NZ624059A (en) Therapeutic applications of activation of human antigen-presenting cells through dectin-1
MX2011012836A (es) Adyuvantes sinteticos de glucopiranosil-lipido.
WO2009095226A3 (en) NUCLEIC ACIDS COMPRISING FORMULA (NuGlXmGnNv)a AND DERIVATIVES THEREOF AS AN IMMUNOSTIMULATING AGENTS /ADJUVANTS
JP2014521735A5 (enExample)
MX2010004482A (es) Anticuerpos anti-proteina g vsr.
WO2009060281A3 (en) Immune stimulatory oligoribonucleotide analogs containing modified oligophosphate moieties
MA32633B1 (fr) Formes cristallines d'un derive 2-thiazolyl-4-quinolinyl-oxy, un inhibiteur puissant du vhc
JP2013519645A5 (enExample)
JP2013501007A5 (enExample)
JP2013510169A5 (enExample)
WO2011094357A8 (en) Respiratory virus epitopes templated into double stranded coiled -coils and use thereof in immunization
JP2014503593A5 (enExample)
NZ593524A (en) A nonapeptide with anti-tumour activity
JP2015509075A5 (enExample)